Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Anti-CD70 CAR-T (CHT101) in Relapsed and Refractory Systemic Lupus Erythematosus
NCT06946485Phase 1Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in systemic lupus erythematosus (SLE), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Systemic Lupus Erythematosus Responder Index 4 Response at 3 months and Safety Evaluation at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
CHT101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06946485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946485.